Abstract
Urinary tract infections (UTI) remain one of the most common bacterial infections worldwide, affecting hundreds of millions of people each year and contributing substantially to antimicrobial consumption. The rapid rise of antimicrobial resistance (AMR) among uropathogens threatens to undermine standard therapies, making timely, evidence-based innovations in diagnosis, treatment, and stewardship more critical than ever.
The landscape of UTI is being reshaped at an unprecedented pace by converging innovations in precision diagnostics, real‑time antimicrobial surveillance, and clinical implementation. In this special issue, thirteen articles highlight how clinicians might translate these advances into tangible improvements in patients suffering from simple and complex UTIs, from uncomplicated cystitis to septic shock. Taken together, the papers signal a decisive pivot away from the binary question of “urine culture positive or negative” toward a more nuanced approach that integrates rapid pathogen detection, local resistance ecology, stewardship interventions, and patient‑reported outcomes.
Rapid molecular diagnostics: Beyond the limits of standard culture
Standard urine culture (SUC) often misses pathogens in complicated UTI cases. In this study of 56 patients, the Urine-ID™ (Vikor Scientific, USA) multiplex polymerase chain reaction (PCR) test detected uropathogens in 92.9% of cases versus 50% with SUC, including co-infections and cases labeled “Mixed urogenital flora” or negative by SUC. PCR also identified AMR markers, enabling faster, targeted treatment and improved diagnostic accuracy. 1
ATLAS of patient-centered tools in simple and complex UTI
This systematic review identified 16 patient-reported outcome measures (PROMs) and several scoring systems and nomograms used in UTI care. 2 While PROMs enhance patient-centered management, their use lacks standardization. Scoring systems and nomograms support risk prediction and diagnosis but must be tailored to specific UTI types and clinical contexts.
Surveillance of antimicrobial resistance in UTI pathogens
This 5-year cross-sectional study of 2595 UTI patients revealed high resistance rates in key pathogens, particularly Klebsiella pneumoniae and Pseudomonas aeruginosa. Escherichia coli remained largely sensitive to carbapenems, amikacin, and Fosfomycin. 3 These findings support the urgent need for national surveillance systems to guide empirical therapy and inform UTI treatment guidelines.
Nurse-driven protocols reduce CAUTI and catheter use
This pre-/postintervention study at a Veterans Affairs hospital showed that implementing a nurse-driven protocol (NDP) for catheter removal reduced catheter-associated UTI (CAUTI) rates by 73% and decreased device utilization. 4 Multidisciplinary collaboration and data dashboards may enhance uptake of such protocols across acute care settings.
Candida species and antifungal resistance in Vietnam
This cross-sectional study of 102 Candida isolates from urine and vaginal samples in Vietnam found Candida albicans to be the most common species (78.4%), followed by non-albicans strains. 5 Resistance was low to echinocandins and amphotericin B, but some resistance to fluconazole (7.7%) and voriconazole (4.2%) was noted, underscoring the need for local antifungal surveillance.
Reducing ASB overtreatment in the ED: A stepped-wedge trial
This stepped-wedge trial across five Dutch emergency departments (Eds) evaluated a de-implementation strategy to curb overtreatment of asymptomatic bacteriuria (ASB). 6 While it reduced the number of urinalyses and shortened antibiotic duration, it did not significantly lower inappropriate antibiotic use for ASB.
Eight years of pediatric UTI stewardship: Adapting to resistance trends
This 8-year quasi-experimental study evaluated a pediatric antimicrobial stewardship program for UTIs. Guideline adherence peaked postintervention, while cephalosporin use and resistance to co-amoxiclav increased. 7 Findings underscore the need for sustained, locally tailored stewardship to adapt to evolving resistance patterns.
CAUTIs in COVID-19 ICU patients: Prevalence, pathogens, and outcomes
In this retrospective cohort study of 201 ICU COVID-19 patients, 28% developed catheter-associated UTIs, predominantly caused by multidrug-resistant K. pneumoniae. 8 CAUTIs were linked to longer ICU stays, increased ventilation needs, and higher mortality, emphasizing the need for robust infection control and antimicrobial stewardship.
Antimicrobial resistance trends in urosepsis: A 4-year review
This retrospective study of 237 urosepsis cases (2017–2020) found Gram-negative bacteria to be the predominant pathogens (75%), with high sensitivity to carbapenems and amikacin. 9 Resistance to fluoroquinolones increased annually. Given the rising threat of ESBL- and carbapenem-resistant strains, fluoroquinolones should be avoided empirically, highlighting the need for ongoing surveillance and antimicrobial stewardship.
Fournier’s Gangrene: Scoring systems and practical management guide
This review outlines four Fournier’s Gangrene (FG) specific scoring systems used to estimate mortality risk and presents a stepwise management algorithm from resuscitation to long-term follow-up. 10 Effective care of FG requires timely surgical intervention and multidisciplinary input. Despite improved outcomes, FG remains a high-mortality condition, highlighting the need for personalized care and quality-of-life-focused research.
Trends in antimicrobial resistance among Gram-negative uropathogens: A 9-year analysis
This review analyzed over 164,000 Gram-negative UTIs from 650,000 urine cultures (2014–2022) in a UK referral centre. 11 Resistance remained low for Amikacin and Gentamicin but rose for Cefalexin, Co-Amoxiclav, and Nitrofurantoin. Despite some declines, AMR trends remain dynamic, highlighting the need for ongoing surveillance to guide empiric UTI treatment.
Isolated renal and urinary tract aspergillosis: A systematic review of clinical features and outcomes
This systematic review looked at 91 cases of isolated renal and urinary aspergillosis from 76 papers (1925–2023). Most patients were immunocompromised males presenting with renal involvement. 12 Amphotericin B and azole regimens were commonly used, with a 24.4% mortality rate. No significant outcome differences were found between treatment types or nephrectomy status.
Bridging the gap: Patient and clinician perspectives on recurrent uncomplicated UTIs
Recurrent uncomplicated UTIs significantly affect patients’ physical and mental well-being. A disconnect between patients and healthcare professionals (HCPs) often leads to inadequate communication and overlooked psychological distress. This article highlights shared perspectives from patients and HCPs, emphasizing the need for improved dialogue, education on antimicrobial resistance, and patient-centered care to enhance outcomes. 13
Conclusion
This special issue underscores a pivotal shift in UTI management, from traditional diagnostic and treatment paradigms to a more nuanced, patient-centered, and AMR awareness. Innovations in rapid diagnostics, antimicrobial surveillance, stewardship strategies, and multidisciplinary care are driving improvements across simple and complex UTI cases. However, persistent challenges such as rising AMR, communication gaps, and variability in care highlight the need for continued research, education, and system-wide implementation of evidence-based practices.
Looking ahead, the collective insights from these studies point to several emerging priorities, including integrating precision diagnostics into routine workflows, expanding real-time, region-specific AMR surveillance, embedding stewardship principles across all care settings, and aligning research agendas with patient-reported outcomes and quality-of-life measures. Equally important will be cross-disciplinary collaboration to ensure that novel technologies and evidence-based strategies are implemented at scale, globally. By focusing on these priorities, the field can move closer to delivering truly personalized, effective, and sustainable UTI care in the decade ahead.
